GM-CSF and low-dose araC treatment of AML in prolonged hypoplasia with residual leukemic cells after induction chemotherapy.
We describe a case with acute myelogenous leukemia (AML; M2) who developed prolonged marrow hypoplasia with residual leukemic blasts and recurrent infections after induction chemotherapy. He was treated successfully with a sequential treatment of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and low-dose cytosine arabinoside (LD AraC). To the best of our knowledge this is the first reported case of a successful treatment of a patient with AML, who showed prolonged markedly hypocellular bone marrow with significant residual leukemic cells after induction chemotherapy, with a sequential treatment of GM-CSF and LD AraC.
Min
Y H
YH
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim
S E
SE
Lee
S T
ST
Lee
S J
SJ
Hahn
J S
JS
Ko
Y W
YW
D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000188:drug therapy*; D003561:Cytarabine / Q000008:administration & dosage*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged
D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor